Dihon Acquisition Doubles Bayer’s Consumer Health Presence In China
This article was originally published in The Tan Sheet
Executive Summary
Bayer acquired its second Chinese consumer health care firm to gain market share amid the country’s OTC consolidation trend. Dihon specializes in antifungal creams and herbal drugs for women’s and traditional Chinese medicines.
You may also be interested in...
China OTC Drug Sales Pummeled By Pseudoephedrine Restrictions
Multinational cold and cough OTC products have suffered a serious setback in China, as government restricts usage of drugs containing pseudoephedrine.
Bayer Increases Chinese Presence With Topsun Cough/Cold Buy
Bayer expects its purchase of Topsun Science & Technology's nonprescription cough and cold portfolio to "substantially increase Bayer Consumer Care's presence in China, one of the fastest growing OTC markets in the world," the firm states Oct. 25
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.